Fr San News Today

Regeneron hopes to limit the damage from the expiration of the patent on its key drug Eylea with a new version of the treatment.

By Adria Calatayud Sanofi is scheduled to report results for the fourth quarter on Thursday. Here is what you need to know. SALES FORECAST: Analysts expect...

By Ben Glickman Regeneron Pharmaceuticals and Sanofi's Dupilumab received approval from the U.S. Food and Drug Administration for a treatment of an esophagus...

UBS analysts shook up their ratings of European drugmakers, including making a double-downgrade of AstraZeneca and a double-upgrade of U.K. rival GSK.

To avoid Medicaid penalties, Glaxo and other drugmakers lowered prices. For popular asthma drug Flovent HFA, the tactic to replace it with a generic backfired.

By Adria Calatayud Sanofi said it would end a clinical-development program for its tusamitamab ravtansine drug candidate after a late-stage trial in...

French pharmaceuticals giant Sanofi on Thursday said it would be halting development of a promising cancer treatment after the cutting-edge candidate failed...

By Denny Jacob Sanofi will terminate its proposed licensing agreement with Maze Therapeutics following opposition from the Federal Trade Commission. The FTC...

Sanofi SA said late Monday it will scuttle an agreement with biotech Maze Therapeutics Inc. after federal trade regulators sought to block it, saying the...

By Adria Calatayud Sanofi aims to generate annual sales of more than 10 billion euros ($10.76 billion) by 2030 from recently launched and future...